Herriot Tabuteau, Chief Executive Officer at Axsome Therapeutics, Inc. (AXSM), sold 90,768 shares at $118.77 ($10.8M) on 2025-10-07, disclosed to the SEC on 2025-10-08.
Scheduled sale ($10.8M) by Chief Executive Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $120.17 | 19,220 | $2.3M | 21.3% |
| 2 | $120.17 | 19,220 | $2.3M | 21.3% |
| 3 | $118.77 | 13,390 | $1.6M | 14.7% |
| 4 | $118.77 | 13,390 | $1.6M | 14.7% |
| 5 | $118.84 | 12,774 | $1.5M | 14.0% |
| 6 | $118.84 | 12,774 |
| $1.5M |
| 14.0% |
| Total | $119.38 avg | 90,768 | $10.8M | 100% |
| Filing → |
| AXSM | SELL | 2026-06-09 | $12.0M | — | Filing → |
| AXSM | SELL | 2026-02-02 | $6.0M | — | Filing → |
| AXSM | SELL | 2026-01-07 | $23.9M | — | Filing → |